The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000694314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/05/2026
Date registered
Help: Date registered
11/06/2026
Date last updated
Help: Date last updated
10/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Safety Study of ARG-397 in Healthy Adult Participants
Scientific title
A Phase 1, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARG-397 in Healthy Adult Participants
Additional trial identifiers [1] 316718 0
ARG-397-HNV-101
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Thromboembolic disorders 340994 0
Condition category
Condition code
Blood 337135 337135 0 0
Clotting disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
There are six dose cohorts planned for this study. Cohorts 1-4 and 6 will receive single subcutaneous (SC) injections of ARG-397. Cohort 5 (optional) will evaluate a single planned intravenous (IV) dose of ARG-397. A registered nurse will administer the study intervention (ARG-397 or placebo) in the clinical research unit.

The planned SC dose levels include up to 100mg (Cohort 1), 300mg (Cohort 2) and 600mg (Cohort 3). Following a review of the available safety and PK data for Cohorts 1-3, the Sponsor will determine the doses to be evaluated in 3 subsequent cohorts. All cohorts will enroll 8 participants randomized in a 6:2 ratio of ARG-397 to placebo.

For each cohort, two sentinel participants (one randomized to ARG-397 and one randomized to placebo) will be dosed first. Sentinel participants will be monitored and evaluated for safety and tolerability for up to 48 hours following dosing.

Participants will remain in the clinical research unit for 7 days following dosing to enable safety surveillance, Pharmacokinetic (PK) sampling and Pharmacodynamic (PD) assessments. After discharge, participants will return for outpatient follow up through 6 months post-dose.
Intervention code [1] 333406 0
Treatment: Drugs
Description of the comparator or control
A placebo (normal saline) will be used as the control group in this study.
Control group
Placebo

Outcomes
Primary outcome [1] 344648 0
To evaluate the safety of ARG-397 as a single-dose in healthy adult participants
Timepoint [1] 344648 0
All adverse events will be recorded from the time of signing consent through the end-of-study visit. Clinical lab safety tests, coagulation parameters, ECGs, vital signs and physical examinations will be collected at Baseline through the End of Study (EOS) visit.
Primary outcome [2] 344649 0
To evaluate the tolerability of ARG-397 as a single-dose in healthy adult participants
Timepoint [2] 344649 0
Local tolerability assessed at Baseline through the EOS visit.
Primary outcome [3] 344650 0
To characterize the plasma pharmacokinetics (PK) of single ascending doses of ARG-397 in healthy adult participants
Timepoint [3] 344650 0
Blood samples will be collected for plasma PK analysis at the following timepoints: On Day 1, blood samples for PK analysis will be collected at predose and 3 timepoints post-dose for SC dosing (Cohorts 1-4 and 6): predose, 2hr, 4hr and 8hrs post dose. On day 1, blood samples for PK analysis will be collected at predose and 0.25hr, 1hr, 2hr, 4hr, 6hr and 8hrs post-dose for IV dosing (Cohort 5). For all participants PK blood samples will also be collected once on days 2-8, day 15, day 22, day 29, day 43, day 57, day 77, day 105, and day 155.
Secondary outcome [1] 461451 0
Nil
Timepoint [1] 461451 0
Nil

Eligibility
Key inclusion criteria
1. Able to provide written informed consent and willing to comply with trial requirements,
2. Age 18 to 65 years.
3. In good health and able to abstain from prescription and over the counter (OTC) medications.
4. Female participants must have a confirmation of postmenopausal or surgically sterile status. Male participants with female partners of child-bearing potential must agree to meet the contraception requirements from the time of study drug administration until 36 weeks after last dose of study drug.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. History of an abnormal bleeding after trauma or intervention.
2. Predisposition for bruising or any other kind of spontaneous bleeding.
3. Presence or family history of bleeding disorder, such as Hemophilia A, Hemophilia B, Wiskott-Aldrich syndrome, or von Willebrand disease (vWD).
4. Any planned surgery or any planned buccal, dental, ear, nose, throat, or genitourinary intervention in the 6 months following enrollment (dosing). Routine dental exams, dental cleanings or other checkups are allowed.
5. History of stroke, transient ischemic attack, or traumatic or non-traumatic intracranial bleed.
6. History of acute, subacute, or chronic pericarditis.
7. Regular use of medications that increase the risk of bleeding, including antiplatelet agents (such as aspirin), anticoagulants, or fibrinolytic agents.
8. Chronic use of OTC medications, corticosteroids or NSAIDs within 14 days prior to dosing.
9. History of allergic reactions to monoclonal antibodies or antibody fragments.
10. History of clinically significant cardiovascular disease, peripheral vascular disease, cardiopulmonary disease, diabetes, anemia or thrombocytopenia.
11. History of bone marrow or solid organ transplantation.
12. History of clinically significant ECG abnormalities or significant arrhythmias. Known family history of long QT syndrome.
13. Required a transfusion within 3 months.
14. Recent (within 2 months) bacterial, protozoal, viral, or parasitic infection that required systemic treatment.
15. History of active tuberculosis infection or systemic fungal disease.
16. Human immunodeficiency virus (HIV) infection or HIV seropositivity at Screening.
17. History of malignancy (except non-melanoma skin cancer or cervical in situ).
18. History of significant multiple and/or severe allergies (including latex gloves), anaphylaxis, or had an anaphylactic reaction, significant intolerability or immediate hypersensitivity reaction to prescription or nonprescription drugs or food.
19. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
20. Participation in any clinical research trial evaluating another investigational drug (including biologics) or therapy (including specific immunotherapy) within 30 days of the last dose of a small molecule, 90 days of the last dose of a biologic or >/=5 half-lives (whichever is longer), prior to Screening. No waiting period is required after participation in an observational study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A computerized randomization list will be created by an unblinded statistician or designee. Subjects will be randomized to receive either ARG-397 or placebo.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computerized randomization list will be used.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29245 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 45554 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 321323 0
Commercial sector/Industry
Name [1] 321323 0
Arguello Biosciences, Inc.
Country [1] 321323 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Arguello Biosciences, Inc.
Address
Country
United States of America
Secondary sponsor category [1] 324056 0
Commercial sector/Industry
Name [1] 324056 0
InClin Pty Ltd
Address [1] 324056 0
Country [1] 324056 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319855 0
Bellberry Human Research Ethics Committee E
Ethics committee address [1] 319855 0
Ethics committee country [1] 319855 0
Australia
Date submitted for ethics approval [1] 319855 0
01/04/2026
Approval date [1] 319855 0
01/05/2026
Ethics approval number [1] 319855 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148630 0
Prof Sepehr Shakib
Address 148630 0
CMAX Clinical Research, Ground Floor, 21-24 North Terrace, Adelaide, SA 5000
Country 148630 0
Australia
Phone 148630 0
+61 8 7088 7900
Fax 148630 0
Email 148630 0
Contact person for public queries
Name 148631 0
Mr Taylor Kilfoil
Address 148631 0
InClin Pty Ltd, Suite 210, 25/29 Berry Street, North Sydney, NSW, Australia, 2060.
Country 148631 0
Australia
Phone 148631 0
+61 408 880 403
Fax 148631 0
Email 148631 0
Contact person for scientific queries
Name 148632 0
Mr Taylor Kilfoil
Address 148632 0
InClin Pty Ltd, Suite 210, 25/29 Berry Street, North Sydney, NSW, Australia, 2060.
Country 148632 0
Australia
Phone 148632 0
+61 408 880 403
Fax 148632 0
Email 148632 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.